|
gptkbp:instanceOf
|
gptkb:brand
gptkb:drug
|
|
gptkbp:activeIngredient
|
docetaxel
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvalYear
|
1996
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:L01CD02
|
|
gptkbp:CASNumber
|
gptkb:114977-28-5
|
|
gptkbp:chemicalFormula
|
C43H53NO14
|
|
gptkbp:contraindication
|
severe liver impairment
hypersensitivity to docetaxel
|
|
gptkbp:developedBy
|
gptkb:Sanofi-Aventis
|
|
gptkbp:drugClass
|
taxane
|
|
gptkbp:eliminationHalfLife
|
11 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Taxotere
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Sanofi
|
|
gptkbp:mechanismOfAction
|
inhibits microtubule depolymerization
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
fatigue
hair loss
peripheral neuropathy
neutropenia
fluid retention
|
|
gptkbp:synonym
|
docetaxel injection
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
gptkb:cancer
prostate cancer
head and neck cancer
gastric cancer
|
|
gptkbp:bfsParent
|
gptkb:Rhône-Poulenc
gptkb:Sanofi-Aventis
gptkb:赛诺菲
|
|
gptkbp:bfsLayer
|
6
|